Familial Adenomatous Polyposis
Top Cited Papers
- 1 February 2006
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 101 (2) , 385-398
- https://doi.org/10.1111/j.1572-0241.2006.00375.x
Abstract
Familial adenomatous polyposis (FAP) is an autosomal-dominant colorectal cancer syndrome, caused by a germline mutation in the adenomatous polyposis coli (APC) gene, on chromosome 5q21. It is characterized by hundreds of adenomatous colorectal polyps, with an almost inevitable progression to colorectal cancer at an average age of 35 to 40 yr. Associated features include upper gastrointestinal tract polyps, congenital hypertrophy of the retinal pigment epithelium, desmoid tumors, and other extracolonic malignancies. Gardner syndrome is more of a historical subdivision of FAP, characterized by osteomas, dental anomalies, epidermal cysts, and soft tissue tumors. Other specified variants include Turcot syndrome (associated with central nervous system malignancies) and hereditary desmoid disease. Several genotype–phenotype correlations have been observed. Attenuated FAP is a phenotypically distinct entity, presenting with fewer than 100 adenomas. Multiple colorectal adenomas can also be caused by mutations in the human MutY homologue (MYH) gene, in an autosomal recessive condition referred to as MYH associated polyposis (MAP). Endoscopic screening of FAP probands and relatives is advocated as early as the ages of 10–12 yr, with the objective of reducing the occurrence of colorectal cancer. Colectomy remains the optimal prophylactic treatment, while the choice of procedure (subtotal vs proctocolectomy) is still controversial. Along with identifying better chemopreventive agents, optimizing screening of extracolonic cancers and applying new radiological and endoscopic technology to the diagnosis and management of extracolonic features are the major challenges for the future.Keywords
This publication has 151 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomasInternational Journal of Cancer, 2004
- Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposisInternational Journal of Cancer, 2001
- Fertility after ileal pouch–anal anastomosis in women with ulcerative colitisBritish Journal of Surgery, 1999
- Photodynamic therapy for polyps in familial adenomatous polyposis—a pilot studyEuropean Journal Of Cancer, 1995
- Phenotype and cancer risk of various polyposis syndromesEuropean Journal Of Cancer, 1995
- Mutations of theAPC adenomatous polyposis coli) geneHuman Mutation, 1993
- Risk of hepatoblastoma in familial adenomatous polyposisThe Journal of Pediatrics, 1991
- Prevalence and Importance of Pigmented Ocular Fundus Lesions in Gardner's SyndromeNew England Journal of Medicine, 1987